SAB Biotherapeutics (SABSW) Stock Price, News & Analysis

Company Overview

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of fully human polyclonal antibody therapeutics. The company’s core technology, known as the Transchromosomic (Tc) Bovine platform, leverages genetically engineered cattle to produce large volumes of human antibodies in response to targeted antigens. These antibodies are designed to treat a range of infectious diseases and immunological disorders, offering a complementary approach to monoclonal antibodies and traditional vaccines.

The company’s lead programs focus on combating high-priority pathogens, including emerging coronaviruses and other viral threats. SAB-185, its polyclonal antibody candidate for COVID-19, has advanced through clinical trials under U.S. Food and Drug Administration oversight. In addition to its proprietary pipeline, SAB Biotherapeutics collaborates with government agencies, academic institutions and pharmaceutical partners to explore applications of its platform for biodefense and public health preparedness.

Beyond its infectious-disease portfolio, SAB Biotherapeutics is investigating the use of human polyclonal antibodies for the treatment of rare immunodeficiencies and chronic conditions. The company offers contract development and manufacturing services, enabling external organizations to leverage its Tc Bovine system for rapid antibody generation. This service model underscores SAB’s commitment to expanding access to novel immunotherapeutics across therapeutic areas.

Founded in 2012 as an outgrowth of academic research into bovine genetics, SAB Biotherapeutics is headquartered in Sioux Falls, South Dakota, with research and development facilities in Massachusetts. In 2020, the company completed its listing on the Nasdaq Capital Market under the ticker SABSW, positioning it to advance its pipeline through late-stage clinical programs and strategic partnerships. SAB’s leadership team comprises seasoned biopharma executives and scientific founders dedicated to translating the Tc Bovine platform into life-saving therapies worldwide.

Key Stats

• Today's Range: $0.03 to $0.03
• 50-Day Range: $0.02 to $0.04
• 52-Week Range: $0.02 to $0.18
• Volume: 25,218 shs
• Average Volume: 28,180 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SABSW Stock Analysis - Frequently Asked Questions

How have SABSW shares performed this year?

SAB Biotherapeutics' stock was trading at $0.0753 at the beginning of the year. Since then, SABSW stock has decreased by 59.8% and is now trading at $0.0303.

How do I buy shares of SAB Biotherapeutics?

Shares of SABSW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SABSW
• CIK: 1833214
• Web: www.sabbiotherapeutics.com
• Phone: 605-679-6980
• Fax: N/A
• Employees: 140
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A